Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Pinnbrook Capital Management LP

Pinnbrook Capital Management LP reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 76.3% in the fourth quarter, HoldingsChannel reports. The fund owned 96,851 shares of the company’s stock after selling 311,115 shares during the quarter. Pinnbrook Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $3,023,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares during the period. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after acquiring an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. lifted its stake in Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 14.8% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Finally, Rubric Capital Management LP lifted its stake in Teva Pharmaceutical Industries by 1.8% during the second quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after purchasing an additional 450,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent research reports. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Barclays increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Stock Down 0.3%

Shares of NYSE:TEVA opened at $34.21 on Friday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The company has a market cap of $39.33 billion, a PE ratio of 25.72, a price-to-earnings-growth ratio of 3.32 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The firm has a 50 day simple moving average of $31.76 and a 200 day simple moving average of $30.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Insider Activity

In related news, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares in the company, valued at $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,280,269 shares of company stock valued at $42,755,980 in the last ninety days. Corporate insiders own 0.54% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.